北京百奥创新科技有限公司
全国咨询热线:15522676233
IGFBP-3, Intact ELISA
  • 品牌:Ansh Labs
  • 产地:国外
  • 型号:10μL
  • 货号:AL-149
  • 发布日期: 2022-08-25
  • 更新日期: 2024-08-12
产品详请
产地 国外
保存条件 详询
品牌 Ansh Labs
货号 AL-149
用途 详询
检测方法 详询
CAS编号
保质期 详询
适应物种 详询
检测限 详询
数量 详询
包装规格 10μL
标记物 详询
纯度 详询%
样本 详询
应用 详询
是否进口

Product Description:Insulin-like growth factor binding protein-3 (IGFBP-3) is a 264-amino acid peptide (MW 29 kD) produced by the liver as well as other tissues. It is the most abundant of a group of IGFBPs that transport, and control bioavailability and half-life of insulin-like growth factors (IGF), in particular IGF-I, the major mediator of the anabolic- and growth-promoting effects of growth hormone (GH).The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II, thus prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Most of the IGFBP-3 in plasma is present as the high molecular weight ternary complex, however, small amounts of free IGFBP-3 are also found.

IGFBP-3 also exhibits intrinsic growth-regulating effects that are not yet fully understood, but have evoked interest with regards to a possible role of IGFBP-3 as a prognostic tumor marker. Low IGFBP-3 and IGF-I levels are observed in GH deficiency or GH resistance, also epidemiologic studies suggest that low IGFBP-3 is associated with greater risk of aggressive, metastatic prostate cancers. The elevated serum IGFBP-3 and IGF-I levels indicate a sustained overproduction of GH, or excessive rhGH therapy. Both conditions are associated with generalized organomegaly, hypertension, diabetes, cardiomyopathy, osteoarthritis, and diminished longevity.

The Ansh Labs Intact IGFBP-3 Assay uses an acidification and neutralization method to dissociate Intact IGFBP-3 from all the binding subunits. Intact IGFBP-3 levels are quantified in the extracted samples using a highly sensitive and specific Intact IGFBP-3 ELISA. Total IGFBP-3 levels can be measured using Total IGFBP-3 ELISA (AL-120).

The concentration of bioactive IGF-I, total IGFBP-3 and intact IGFBP-3 in biological fluid can be measured accurately using immunoassay methods (Bioactive IGF-1 ELISA; AL-122, IGF-I inhibition mAb capture and IGF-1 C-terminal mAb) detection; Total IGFBP-3 ELISA; AL-120, C-terminal IGFBP-3 capture and detection mAb; and Intact IGFBP-3 ELISA; AL-149, C-terminal mAb capture and N-terminal mAb detection, respectively). The ratio of total to Intact IGFBP-3 concentration measured in individual subject over time will help normalizes the IGFBP-3 variability between subjects. The immunoassay methods designed for the measurement of bioactive IGF-I, total and Intact IGFBP-3 in patient samples could be of practical value for the diagnosis or prediction of various pathologies including growth abnormalities and cancer.

Regulatory Status:For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Packaging:96 well microtiter

Detection:HRP-based ELISA, colorimetric detection by dual wavelength absorbance at 450 nm and 630 nm as reference filter

Dynamic Range:6, 1.7-75 ng/mL

Limit of Detection:0.08 ng/mL

Sample Type:Serum

Assay Time:1.5 hours

Species Reactivity:Bovine, Caprine, Human, Mouse, Rabbit

Shelf Life:24 months